Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin

J. J. Fiore, D. P. Kelsen, Richard J. Gralla, E. S. Casper, G. Magill, E. Cheng, M. Ochoa

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Adenocarcinoma of unknown primary origin (ACUP) is a common oncologic problem for which there is no standard therapy. Forty-two patients with metastatic tumor were identified as having ACUP after extensive evaluation failed to reveal a primary site of disease. They were treated with an investigational chemotherapy regimen consisting of vindesine and doxorubicin. Of the 38 evaluable patients, six (16%) had major responses to chemotherapy. The median duration of response was 4 months. The median survival of the responding patients has not been reached, but is >8 months. The median survival of the nonresponding patients was 6 months. Vindesine and doxorubin were well tolerated. The major toxicity was leukopenia, with a median wbc count nadir of 2600/mm3. We conclude that the combination of vindesine and doxorubicin has some activity in ACUP, but does not improve the response rate seen with other regimens.

Original languageEnglish (US)
Pages (from-to)591-594
Number of pages4
JournalCancer Treatment Reports
Volume69
Issue number6
StatePublished - 1985
Externally publishedYes

Fingerprint

Vindesine
Doxorubicin
Adenocarcinoma
Drug Therapy
Survival
Leukopenia
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fiore, J. J., Kelsen, D. P., Gralla, R. J., Casper, E. S., Magill, G., Cheng, E., & Ochoa, M. (1985). Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin. Cancer Treatment Reports, 69(6), 591-594.

Adenocarcinoma of unknown primary origin : Treatment with vindesine and doxorubicin. / Fiore, J. J.; Kelsen, D. P.; Gralla, Richard J.; Casper, E. S.; Magill, G.; Cheng, E.; Ochoa, M.

In: Cancer Treatment Reports, Vol. 69, No. 6, 1985, p. 591-594.

Research output: Contribution to journalArticle

Fiore, JJ, Kelsen, DP, Gralla, RJ, Casper, ES, Magill, G, Cheng, E & Ochoa, M 1985, 'Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin', Cancer Treatment Reports, vol. 69, no. 6, pp. 591-594.
Fiore JJ, Kelsen DP, Gralla RJ, Casper ES, Magill G, Cheng E et al. Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin. Cancer Treatment Reports. 1985;69(6):591-594.
Fiore, J. J. ; Kelsen, D. P. ; Gralla, Richard J. ; Casper, E. S. ; Magill, G. ; Cheng, E. ; Ochoa, M. / Adenocarcinoma of unknown primary origin : Treatment with vindesine and doxorubicin. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 6. pp. 591-594.
@article{d54f62025749452db8f2abb70416cf4e,
title = "Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin",
abstract = "Adenocarcinoma of unknown primary origin (ACUP) is a common oncologic problem for which there is no standard therapy. Forty-two patients with metastatic tumor were identified as having ACUP after extensive evaluation failed to reveal a primary site of disease. They were treated with an investigational chemotherapy regimen consisting of vindesine and doxorubicin. Of the 38 evaluable patients, six (16{\%}) had major responses to chemotherapy. The median duration of response was 4 months. The median survival of the responding patients has not been reached, but is >8 months. The median survival of the nonresponding patients was 6 months. Vindesine and doxorubin were well tolerated. The major toxicity was leukopenia, with a median wbc count nadir of 2600/mm3. We conclude that the combination of vindesine and doxorubicin has some activity in ACUP, but does not improve the response rate seen with other regimens.",
author = "Fiore, {J. J.} and Kelsen, {D. P.} and Gralla, {Richard J.} and Casper, {E. S.} and G. Magill and E. Cheng and M. Ochoa",
year = "1985",
language = "English (US)",
volume = "69",
pages = "591--594",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Adenocarcinoma of unknown primary origin

T2 - Treatment with vindesine and doxorubicin

AU - Fiore, J. J.

AU - Kelsen, D. P.

AU - Gralla, Richard J.

AU - Casper, E. S.

AU - Magill, G.

AU - Cheng, E.

AU - Ochoa, M.

PY - 1985

Y1 - 1985

N2 - Adenocarcinoma of unknown primary origin (ACUP) is a common oncologic problem for which there is no standard therapy. Forty-two patients with metastatic tumor were identified as having ACUP after extensive evaluation failed to reveal a primary site of disease. They were treated with an investigational chemotherapy regimen consisting of vindesine and doxorubicin. Of the 38 evaluable patients, six (16%) had major responses to chemotherapy. The median duration of response was 4 months. The median survival of the responding patients has not been reached, but is >8 months. The median survival of the nonresponding patients was 6 months. Vindesine and doxorubin were well tolerated. The major toxicity was leukopenia, with a median wbc count nadir of 2600/mm3. We conclude that the combination of vindesine and doxorubicin has some activity in ACUP, but does not improve the response rate seen with other regimens.

AB - Adenocarcinoma of unknown primary origin (ACUP) is a common oncologic problem for which there is no standard therapy. Forty-two patients with metastatic tumor were identified as having ACUP after extensive evaluation failed to reveal a primary site of disease. They were treated with an investigational chemotherapy regimen consisting of vindesine and doxorubicin. Of the 38 evaluable patients, six (16%) had major responses to chemotherapy. The median duration of response was 4 months. The median survival of the responding patients has not been reached, but is >8 months. The median survival of the nonresponding patients was 6 months. Vindesine and doxorubin were well tolerated. The major toxicity was leukopenia, with a median wbc count nadir of 2600/mm3. We conclude that the combination of vindesine and doxorubicin has some activity in ACUP, but does not improve the response rate seen with other regimens.

UR - http://www.scopus.com/inward/record.url?scp=0021881093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021881093&partnerID=8YFLogxK

M3 - Article

C2 - 4016765

AN - SCOPUS:0021881093

VL - 69

SP - 591

EP - 594

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -